Soluble inflammatory markers as predictors of virological response in patients with chronic hepatitis C virus infection treated with interferon-α plus ribavirin

Memorias do Instituto Oswaldo Cruz

Volumn 106, Issue 1, 2011, Pages 38-43

  Moura, Alexandre Sampaio ^a   Carmo, Ricardo Andrade ^a   Teixeira, Antonio Lucio ^a   Teixeira, Mauro Martins ^a   da Costa Rocha, Manoel Otávio ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Chemokines; Hepatitis C; Interferon alpha; Tumour necrosis factor receptors

Indexed keywords

HEPATITIS C VIRUS;

EID: 79951489643     PISSN: 00740276     EISSN: 16788060     Source Type: Journal    
DOI: 10.1590/S0074-02762011000100006     Document Type: Article

References (50)

1. Abu-Khabar KS, Armstrong JA, Ho M 1992. Type I interferons (IFN-alpha and -beta) suppress cytotoxin (tumor necrosis factor-alpha and lymphotoxin) production by mitogen-stimulated human peripheral blood mononuclear cell. J Leukoc Biol 52: 165-172.
2. Apolinario A, Diago M, Lo Iacono O, Lorente R, Pérez C, Majano PL, Clemente G, García-Monzón C 2004. Increased circulating and intrahepatic T-cell-specific chemokines in chronic hepatitis C: relationship with the type of virological response to peginterferon plus ribavirin combination therapy. Aliment Pharmacol Ther 19: 551-562.
3. Apolinario Fernández de Sousa A, García Monzón C 2003. Role of chemokines in the pathogenesis of liver diseases. Rev Esp Enferm Dig 95: 614-620.
4. Asselah T, Estrabaud E, Bieche I, Lapalus M, De Muynck S, Vidaud M, Saadoun D, Soumelis V, Marcellin P 2010. Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin. Liver Int 30: 1259-1269.
5. Baggiolini M, Dewald B, Moser B 1997. Human chemokines: an update. Annu Rev Immunol 15: 675-705.
6. Bedossa P, Poynard T 1996. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 24: 289-293.
7. Bonecchi R, Bianchi G, Bordignon PP, D'Ambrosio D, Lang R, Borsatti A, Sozzani S, Allavena P, Gray PA, Mantovani A, Sinigaglia F 1998. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med 187: 129-134.
8. Brown RS Jr, Gaglio PJ 2003. Scope of worldwide hepatitis C problem. Liver Transpl 9: S10-13.
9. Butera D, Marukian S, Iwamaye AE, Hembrador E, Chambers TJ, Di Bisceglie AM, Charles ED, Talal AH, Jacobson IM, Rice CM, Dustin LB 2005. Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C. Blood 106: 1175-1182.
10. Charo IF, Ransohoff RM 2006. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 354: 610-621.
11. Cramp ME, Rossol S, Chokshi S, Carucci P, Williams R, Naoumov NV 2000. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology 118: 346-355.
12. de Araújo ES, Mendonça JS, Barone AA, Gonçales FL Jr, Ferreira MS, Focaccia R, Pawlotsky JM 2007. Consensus of the Brazilian Society of Infectious Diseases on the management and treatment of hepatitis C. Braz J Infect Dis 11: 446-450.
13. Diago M, Castellano G, García-Samaniego J, Pérez C, Fernández I, Romero M, Iacono OL, García-Monzón C 2006. Association of pretreatment serum interferon gamma inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C. Gut 55: 374-379.
14. Feld JJ, Hoofnagle JH 2005. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 436: 967-972.
15. Frese M, Barth K, Kaul A, Lohmann V, Schwärzle V, Bartenschlager R 2003. Hepatitis C virus RNA replication is resistant to tumour necrosis factor-alpha. J Gen Virol 84: 1253-1259.
16. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347: 975-982.
17. Gerard C, Rollins BJ 2001. Chemokines and disease. Nat Immunol 2: 108-115.
18. Guidotti LG, Chisari FV 2001. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol 19: 65-91.
19. Joyce DA, Gibbons DP, Green P, Steer JH, Feldmann M, Brennan FM 1994. Two inhibitors of pro-inflammatory cytokine release, interleukin-10 and interleukin-4, have contrasting effects on release of soluble p75 tumor necrosis factor receptor by cultured monocytes. Eur J Immunol 24: 2699-2705.
20. Kamal SM, Fehr J, Roesler B, Peters T, Rasenack JW 2002. Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C. Gastroenterology 123: 1070-1083.
21. Kamal SM, Ismail A, Graham CS, He Q, Rasenack JW, Peters T, Tawil AA, Fehr JJ, Khalifa Kel S, Madwar MM, Koziel MJ 2004. Pegylated interferon alpha therapy in acute hepatitis C: relation to hepatitis C virus-specific T cell response kinetics. Hepatology 39: 1721-1731.
22. Koziel MJ 1999. Cytokines in viral hepatitis. Semin Liver Dis 19: 157-169.
23. Kunkel SL 1999. Through the looking glass: the diverse in vivo activities of chemokines. J Clin Invest 104: 1333-1334.
24. Lagging M, Romero AI, Westin J, Norkrans G, Dhillon AP, Pawlotsky JM, Zeuzem S, von Wagner M, Negro F, Schalm SW, Haagmans BL, Ferrari C, Missale G, Neumann AU, Verheij-Hart E, Hellstrand K 2006. IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. Hepatology 44: 1617-1625.
25. Lantz M, Malik S, Slevin ML, Olsson I 1990. Infusion of tumor necrosis factor (TNF) causes an increase in circulating TNF-binding protein in humans. Cytokine 2: 402-406.
26. + cells in liver damage and viral control during persistent hepatitis C virus infection. J Hepatol 47: 632-641.
27. Lee SS, Heathcote EJ, Reddy KR, Zeuzem S, Fried MW, Wright TL, Pockros PJ, Häussinger D, Smith CI, Lin A, Pappas SC 2002. Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD). J Hepatol 37: 500-506.
28. Lien E, Liabakk NB, Johnsen AC, Nonstad U, Sundan A, Espevik T 1995. Polymorphonuclear granulocytes enhance lipopolysaccharide-induced soluble p75 tumor necrosis factor receptor release from mononuclear cells. Eur J Immunol 25: 2714-2717.
29. Luster AD 1998. Chemokines-chemotactic cytokines that mediate inflammation. N Engl J Med 338: 436-445.
30. Mackay CR 1997. Chemokines: what chemokine is that? Curr Biol 7: R384-386.
31. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358: 958-965.
32. Marinos G, Naoumov NV, Rossol S, Torre F, Wong PY, Gallati H, Portmann B, Williams R 1995. Tumor necrosis factor receptors in patients with chronic hepatitis B virus infection. Gastroenterology 108: 1453-1463.
33. Mihm U, Herrmann E, Sarrazin C, Zeuzem S 2006. Review article: predicting response in hepatitis C virus therapy. Aliment Pharmacol Ther 23: 1043-1054.
34. Moura AS, Carmo RA, Teixeira AL, Leite VH, Rocha MO 2010. Soluble inflammatory markers as predictors of liver histological changes in patients with chronic hepatitis C virus infection. Eur J Clin Microbiol Infect Dis 29: 1153-1161.
35. Moura AS, Carmo RA, Teixeira AL, Rocha MO 2009. Soluble inflammatory markers as predictors of hepatocellular damage and therapeutic response in chronic hepatitis C. Braz J Infect Dis 13: 375-382.
36. MS - Ministério da Saúde/Secretaria de Atenção à Saúde 2002. Portaria 863 de 04 de novembro de 2002. Protocolo clínico e diretrizes terapêuticas para o tratamento da hepatite viral crônica C. Available from: http://www.saude.ms.gov.br/controle/ShowFile.php?id=2227.
37. Narumi S, Tominaga Y, Tamaru M, Shimai S, Okumura H, Nishioji K, Itoh Y, Okanoue T 1997. Expression of IFN-inducible protein-10 in chronic hepatitis. J Immunol 158: 5536-5544.
38. Nelson DR, Marousis CG, Ohno T, Davis GL, Lau JY 1998. Intrahepatic hepatitis C virus-specific cytotoxic T lymphocyte activity and response to interferon alfa therapy in chronic hepatitis C. Hepatology 28: 225-230.
39. Neuman MG, Benhamou JP, Malkiewicz IM, Akremi R, Shear NH, Asselah T, Ibrahim A, Boyer N, Martinot-Peignoux M, Jacobson-Brown P, Katz GG, Le Breton V, Le Guludec G, Suneja A, Marcellin P 2001. Cytokines as predictors for sustained response and as markers for immunomodulation in patients with chronic hepatitis C. Clin Biochem 34: 173-182.
40. Ono SJ, Nakamura T, Miyazaki D, Ohbayashi M, Dawson M, Toda M 2003. Chemokines: roles in leukocyte development, trafficking, and effector function. J Allergy Clin Immunol 111: 1185-1199.
41. Porteu F, Brockhaus M, Wallach D, Engelmann H, Nathan CF 1991. Human neutrophil elastase releases a ligand-binding fragment from the 75-kDa tumor necrosis factor (TNF) receptor. Comparison with the proteolytic activity responsible for shedding of TNF receptors from stimulated neutrophils. J Biol Chem 266: 18846-18853.
42. Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, Ling MH, Albrecht J 2002. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 122: 1303-1313.
43. Rehermann B, Nascimbeni M 2005. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 5: 215-229.
44. Romero AI, Lagging M, Westin J, Dhillon AP, Dustin LB, Pawlotsky JM, Neumann AU, Ferrari C, Missale G, Haagmans BL, Schalm SW, Zeuzem S, Negro F, Verheij-Hart E, Hellstrand K 2006. Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection. J Infect Dis 194: 895-903.
45. Sousa-Pereira SR, Teixeira AL, Silva LC, Souza AL, Antunes CM, Teixeira MM, Lambertucci JR 2006. Serum and cerebral spinal fluid levels of chemokines and Th2 cytokines in Schistosoma mansoni myeloradiculopathy. Parasite Immunol 28: 473-478.
46. Strader DB, Wright T, Thomas DL, Seeff LB 2004. Diagnosis, management, and treatment of hepatitis C. Hepatology 39: 1147-1171.
47. Tam RC, Pai B, Bard J, Lim C, Averett DR, Phan UT, Milovanovic T 1999. Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile. J Hepatol 30: 376-382.
48. Tilg H 1997. New insights into the mechanisms of interferon alfa: an immunoregulatory and anti-inflammatory cytokine. Gastroenterology 112: 1017-1021.
49. Tilg H, Vogel W, Dinarello CA 1995. Interferon-alpha induces circulating tumor necrosis factor receptor p55 in humans. Blood 85: 433-435.
50. Yamada G, Iino S, Okuno T, Omata M, Kiyosawa K, Kumada H, Hayashi N, Sakai T 2008. Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors. Clin Drug Investig 28: 9-16.